Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VERZENIO
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
- Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- VS-6766+Abema+Fulv in Met HR+/HER- BC
- A Phase II Open Label, Umbrella Study
- ETHAN - ET for Male BC
- Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma and Other Solid Tumors
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
- Abemaciclib With or Without Atezolizumab for mCRPC
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
- ABEMA Alone or in COMBO With MK-6482
- LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
- Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
- A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
- Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
- Abemaciclib + Pembrolizumab In Glioblastoma
- Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
- Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy
- Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
- A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
- Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
- Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Clinical trials list
click for details